Koyanagi Y, et al. - The goal of this trial was to assess the connection between early response to anti-vascular endothelial growth factor (VEGF) treatment and visual prognosis for the treatment of diabetic macular edema (DME). A substantially greater improvement was reported in the visual improvement group (VIG) than in the visual nonimprovement group (VNIG) due to best-corrected visual acuity (BCVA). It was deduced that logMAR BCVA changes from baseline to month 3 (ΔBCVA_M3) could speculate the visual outcome at month 12 in DME patients treated with anti-VEGF drugs.